Sökning: WFRF:(Lista S.) > (2010-2014) > Perspective on Futu...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04339naa a2200493 4500 | |
001 | oai:gup.ub.gu.se/188372 | |
003 | SwePub | |
008 | 240528s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1883722 URI |
024 | 7 | a https://doi.org/10.1016/j.bcp.2013.11.0092 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hampel, Harald4 aut |
245 | 1 0 | a Perspective on Future Role of Biological Markers in Clinical Therapy Trials of Alzheimer's Disease: A Long-Range Point of View Beyond 2020. |
264 | 1 | b Elsevier BV,c 2014 |
520 | a Recent advances in understanding the molecular mechanisms underlying various paths towards the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
700 | 1 | a Lista, Simone4 aut |
700 | 1 | a Teipel, Stefan J4 aut |
700 | 1 | a Garaci, Francesco4 aut |
700 | 1 | a Nisticò, Robert4 aut |
700 | 1 | a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xbleka |
700 | 1 | a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe |
700 | 1 | a Bertram, Lars4 aut |
700 | 1 | a Duyckaerts, Charles4 aut |
700 | 1 | a Bakardjian, Hovagim4 aut |
700 | 1 | a Drzezga, Alexander4 aut |
700 | 1 | a Colliot, Olivier4 aut |
700 | 1 | a Epelbaum, Stéphane4 aut |
700 | 1 | a Broich, Karl4 aut |
700 | 1 | a Lehéricy, Stéphane4 aut |
700 | 1 | a Brice, Alexis4 aut |
700 | 1 | a Khachaturian, Zaven S4 aut |
700 | 1 | a Aisen, Paul S4 aut |
700 | 1 | a Dubois, Bruno4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Biochemical pharmacologyd : Elsevier BVg 88:4, s. 426-449q 88:4<426-449x 1873-2968x 0006-2952 |
856 | 4 | u https://pure.mpg.de/pubman/item/item_1982964_6/component/file_1989744/Hampel.pdf |
856 | 4 8 | u https://gup.ub.gu.se/publication/188372 |
856 | 4 8 | u https://doi.org/10.1016/j.bcp.2013.11.009 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.